Expert Statement: Greg Behar, Recipharm
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Topics
Expert Statement: Alex Del Priore, Syngene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Chad Telgenhof, Sterling Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Thomas Otto and Peter Soelkner, Vetter
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Rohtash Kumar, Veranova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Wilson, Pfizer
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Davuluri Saharsh Rao, Neuland Labs
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Federico Pollano, Rentschler
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Prasad Raje, LGM Pharma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gordon Bates, Lonza
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Kenneth N. Drew, Flamma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ludwig de Mot, EuroAPI
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Frank Wegener, ESIM Chemicals
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Russel Miller, Enzene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: David McErlane and Aris Gennadios, Catalent
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ashu Tandon, Aragen
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Sellig, Adare Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gavin Murdoch, Abzena
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Using Chemistry to Create Net-Zero Value Chains
In this interview, Charlie Tan, CEO of the Global Impact Coalition (GIC), explains the initiative’s scope and describes some key activities.
Productivity in Biopharma Research Picks Up
Technological developments in the pharmaceutical and biotech industry are reflected in increased funding, higher R&D productivity and more product launches. However, the general conditions remain challenging. Incremental change won’t be enough to deliver the results that the market and patients demand, warn industry experts.
Formulating Innovative Concepts
Matthias Hofmann, Group Innovation & Technology Management Director at Azelis, provides an in-depth insight into the company’s innovation activities and the underlying market trends.
Innovation Through Formulation
Anna Bertona, Group CEO at Azelis, looks back on her first six month in this role and gives an insight into her plans for the company's development.
Sustainable Material Adoption in Industrial Sectors
IMCD Industrial Solutions surveyed top customers around the globe on their insights into eight key topics deemed pertinent to sustainability in industrial sectors. This article highlights some of the most important results.
Elixir Group Continues Sustainable Growth Strategy
The Serbian Elixir Group continues to focus clearly on expansion and sustainability.
Positioned for Growth: The New Age of Winning for Chemical Distributors
By enhancing offerings, ensuring performance, managing costs, and embracing sustainability, distributors prove as essential partners for long-term success amidst evolving challenges.
Unleashing CDMO Growth through Effective Pricing
In the rapidly evolving industry of contract development and manufacturing organizations (CDMOs), a well-defined pricing strategy is essential to drive growth and profitability. To stay ahead and participate in the expansion of the market, CDMOs need to transition to a structured value-based pricing approach that considers customer value, complexity, and specific needs.
The Green Power of Catalysis
With more than 80% of all chemical products manufactured using catalytic processes, catalysts are the number one value generator in the chemical industry.
Packaging Industry Drives Circular Economy through Science, Innovation and Consumer Insights
The concept of a circular economy, where materials are recycled and reused, is becoming increasingly important in consumer packaging, driven by regulatory requirements and customer interest.
Spray Drying for Inhalation: the Challenges of Scale-up
When developing an inhaled powder formulation, the drug particles’ properties are critical to successful delivery to the deep lung. The aerodynamic diameter is the key parameter, as it represents how well the particle flies in an air stream.
The Use of Evonik’s Catalysts to Manufacture TFA-free Margarines
When manufacturing specialty edible fats, ensuring that the product has the desired properties – such as a stable shelf life, optimal melting behavior, and texture – is essential.
Providing Solutions by Making the Most of Biomedical Data
Many life science companies generate large swathes of data.
How CDMOs Can Contribute to Pharma Supply even Better
The demand for medicines is increasing rapidly and R&D pipelines have doubled over the last decade.
The Success Story of Biosimilars
With their triumphant advance, biosimilars are also setting in motion the usual market mechanisms. Biopharma interest groups warn against the automatic substitution of originator drugs.
New Biologics and Advanced Therapies
The pharmaceutical market is undergoing a profound transformation, driven by innovation among biologics and advanced therapies (ATs). This shift is not only redefining the treatment landscape but also presenting new opportunities and challenges related to the drug development and manufacturing value chain.
The Evolution of CDMOs
Contract development and manufacturing organizations (CDMOs) are a crucial part of the life sciences industry. Strangely, despite its current prominence, the CDMO industry is a relatively young one. There have been significant developments over its short lifespan, and it is likely that we see even more growth in the years to come.
